PMID- 27544029
OWN - NLM
STAT- MEDLINE
DCOM- 20170522
LR  - 20171127
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 478
IP  - 3
DP  - 2016 Sep 23
TI  - Metformin ameliorates obesity-associated hypertriglyceridemia in mice partly 
      through the apolipoprotein A5 pathway.
PG  - 1173-8
LID - S0006-291X(16)31344-4 [pii]
LID - 10.1016/j.bbrc.2016.08.087 [doi]
AB  - INTRODUCTION: Apolipoprotein A5 (apoA5) is a key regulator of triglyceride (TG) 
      metabolism. This study is to investigate the role of apoA5 in obesity-associated 
      hypertriglyceridemia and metformin-related hypotriglyceridemic actions. METHODS: 
      Two obese mouse models, including high-fat diet-induced obese mice and ob/ob 
      obese mice, were adopted. The effects of low- and high-dose metformin were 
      determined on plasma and hepatic TG and apoA5 of these obese mice. Besides, the 
      effects of metformin on TG and apoA5 were also detected in mouse and human 
      hepatocytes in vitro. RESULTS: (1) Plasma apoA5 levels in the obese mice were 
      markedly elevated and positively correlated with TG. Hepatic TG contents and 
      apoA5 expressions were also remarkably increased in the obese mice. (2) Metformin 
      dose-dependently decreased hepatic and plasma TG and apoA5 in the obese mice. 
      Similarly, metformin dose-dependently reduced cellular TG contents and apoA5 
      expressions in hepatocytes in vitro. Compared to APOA5 knock-down (KD), metformin 
      plus APOA5 KD resulted in more TG reduction of hepatocytes. CONCLUSION: Increased 
      hepatic and plasma apoA5 could be a result of obesity-associated 
      hypertriglyceridemia, and metformin displays hypotriglyceridemic effects on obese 
      mice partly via the apoA5 pathway.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Li, Rong
AU  - Li R
AD  - Department of Stomatology, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Chen, Lu-Zhu
AU  - Chen LZ
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South 
      University, Changsha, China.
FAU - Zhao, Wang
AU  - Zhao W
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South 
      University, Changsha, China.
FAU - Zhao, Shui-Ping
AU  - Zhao SP
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South 
      University, Changsha, China.
FAU - Huang, Xian-Sheng
AU  - Huang XS
AD  - Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South 
      University, Changsha, China. Electronic address: initialhxs@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160817
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Apolipoprotein A-V)
RN  - 0 (Triglycerides)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Animals
MH  - Apolipoprotein A-V/*metabolism
MH  - Body Weight/drug effects
MH  - Hep G2 Cells
MH  - Humans
MH  - Hypertriglyceridemia/blood/complications/*drug therapy/*metabolism
MH  - Male
MH  - Metformin/pharmacology/*therapeutic use
MH  - Mice, Inbred C57BL
MH  - Mice, Obese
MH  - Obesity/blood/complications/*drug therapy/*metabolism
MH  - Triglycerides/blood
OTO - NOTNLM
OT  - Apolipoprotein A5
OT  - Metformin
OT  - Obesity
OT  - Triglyceride
EDAT- 2016/08/22 06:00
MHDA- 2017/05/23 06:00
CRDT- 2016/08/22 06:00
PHST- 2016/07/24 00:00 [received]
PHST- 2016/08/15 00:00 [accepted]
PHST- 2016/08/22 06:00 [entrez]
PHST- 2016/08/22 06:00 [pubmed]
PHST- 2017/05/23 06:00 [medline]
AID - S0006-291X(16)31344-4 [pii]
AID - 10.1016/j.bbrc.2016.08.087 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2016 Sep 23;478(3):1173-8. doi: 
      10.1016/j.bbrc.2016.08.087. Epub 2016 Aug 17.